Clinical trials: Vascular Patients
Coronary Artery Disease
Cangrelor Prasugrel Transition Study
To demonstrate that patients treated with cangrelor can be directly switched to oral prasugrel and that patients treated with prasugrel can be switched to cangrelor without a significant decrease in the extent of inhibition of…
- Trial name
- NCT01852019
- Testing
- Cangrelor, Prasugrel
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Medicines Company
Primary Hypertension
A Study of LY2623091 in Participants With High Blood Pressure
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.
- Trial name
- NCT02194465
- Testing
- LY2623091, Tadalafil, Spironolactone
- Where
- 43 sites in United States, Canada and 1 more
- Volunteers
- 304 people
- Sponsor
- Eli Lilly and Company
Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt
This is a multi-center, single-blind, randomized, active-controlled, clinical trial in Percutaneous Coronary Intervention (PCI) subjects.
- Trial name
- HARMONEE (NCT02073565)
- Testing
- OrbusNeich Combo stent™, Everolimus Eluting Stent (EES)
- Where
- 50 sites in United States, Japan
- Volunteers
- 572 people
- Sponsor
- OrbusNeich
Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
- Trial name
- CHEST-1 (NCT00855465)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 89 sites in United States, Argentina and 24 more
- Volunteers
- 262 people
- Sponsor
- Bayer
Non Hodgkin Lymphoma, Multiple Myeloma
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial.
- Conditions
- Non Hodgkin Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03436771
- Testing
- JCAR017, JCARH125
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Hypertension
Pharmacovigilance and Patient Compliance in Hypertensive Patients
Study to confirm the safety profile of telmisartan (benefit-risk ratio) under normal conditions of use after market launch and to supplement the present data on the safety of telmisartan.
- Trial name
- NCT02200575
- Testing
- Telmisartan
- Volunteers
- 10,333 people
- Sponsor
- Boehringer Ingelheim
Hypertension,Essential
A Study to Evaluate the Efficacy and Safety of AD-224
The purpose of this study is to evaluate the efficacy and safety of AD-224
- Trial name
- NCT06291207
- Testing
- AD-224A, AD-224B, AD-224C
- Where
- South Korea
- Volunteers
- 254 people
- Sponsor
- Addpharma Inc.
Coagulation, Platelet Function
RapidTEG MA Validation
During normal physiological conditions hemostasis (the ability of blood to clot) is kept in homeostatic balance by feedback mechanisms.
- Trial name
- R-TEG MA (NCT01428102)
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Haemonetics Corporation
Multiple Myeloma (MM)
Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)
Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM relapse (cancer has come back) or become non- responsive to treatment and remission gets shorter…
- Trial name
- MEDICI (NCT04721002)
- Where
- 40 sites in United States, Argentina and 20 more
- Volunteers
- 514 people
- Sponsor
- AbbVie
Hypertension
Clinical Characteristics and Medication Satisfaction of Kanarb Tablet in Korean Hypertensive Patient(Kanarb-Hypertension Epidemiology Medication Satisfaction Study)
1. Investigate the clinical characteristics, medication satisfaction and quality of life of anti-hypertensive drugs in Korean hypertensive patients 2.
- Trial name
- K-HEMS (NCT02394392)
- Where
- South Korea
- Volunteers
- 12,691 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Stage II Hypertension
Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension
This study assessed the efficacy and safety of combination therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in patients with stage II Hypertension.
- Trial name
- ACADEMY (NCT01070030)
- Testing
- Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)
- Where
- 3 sites in Thailand
- Volunteers
- 230 people
- Sponsor
- Novartis
Hypertension, Pulmonary
Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension
The main aim of the observational VENTASTEP study was to investigate the association between changes in clinical outcome measures and changes in device outcome measures in PAH patients using the new Breelib nebulizer in a real…
- Trial name
- VENTASTEP (NCT03293407)
- Testing
- Iloprost (Ventavis, BAYQ6256), Breelib nebulizer
- Where
- Germany
- Volunteers
- 31 people
- Sponsor
- Bayer
Hereditary Angioedema
An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema
The purpose of this study was to evaluate the safety and efficacy of extended dosing of donidalorsen administered subcutaneously (SC), with alternative dosing and/or dose frequency with donidalorsen in participants with…
- Trial name
- NCT04307381
- Testing
- Donidalorsen
- Where
- 7 sites in United States, Netherlands
- Volunteers
- 20 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Coronary Artery Disease
Prognostic Assessment of Contrast Echocardiography (PACE Study)
This study will demonstrate whether patients with prognostically-significant myocardial abnormalities detected with AI-700 contrast ECHO have a rate of cardiac death or MI that is higher than that of patients with normal AI-700…
- Trial name
- PACE (NCT00670332)
- Where
- United States
- Volunteers
- 773 people
- Sponsor
- Acusphere
Acute Myocardial Infarction (AMI), Acute Myocardial Infarction of Anterior Wall
Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction
The goal of this phase IIc clinical trial is to learn if recombinant human thymosin beta 4 injection (NL005) works to treat heart damage in people who have had a serious type of heart attack called ST-segment elevation myocardial…
- Conditions
- Acute Myocardial Infarction (AMI), Acute Myocardial Infarction of Anterior Wall, Acute Myocardial Infarction With ST Elevation, Acute Myocardial Infarction of Left Ventricle
- Trial name
- NCT07586865
- Testing
- Recombinant Human Thymosin Beta 4 Injection (NL005)
- Where
- China
- Volunteers
- 189 people
- Sponsor
- Beijing Northland Biotech. Co., Ltd.
Coronary Artery Disease
Objective Confirmation of thе Anti-ischemic Effectiveness of Trimetazidine 80mg Once Daily in Patients With Stable Angina Who Had a History of Myocardial Infarction (METHOD)
METHOD is a prospective observational program that will be conducted in 1centre of the Russian Federation. Prospective follow-up will be for about 6 months.
- Trial name
- METHOD (NCT05210465)
- Testing
- speckle tracking mode of the stress ECHO test with dobutamine
- Where
- 2 sites in Russia
- Volunteers
- 36 people
- Sponsor
- Servier Russia
Cryopyrin Associated Periodic Syndrome
The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
This study will assess the safety, tolerability and efficacy of canakinumab treatment in Canadian patient diagnosed with cryopyrin-associated periodic syndrome over a period of 18 months.
- Trial name
- NCT01105507
- Testing
- canakinumab (company code: ACZ885D)
- Where
- 2 sites in Canada
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines
The purpose of this study was to evaluate the safety, tolerability and efficacy of remibrutinib (LOU064) in adult Japanese patients chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment by H1-antihistamine…
- Trial name
- BISCUIT (NCT05048342)
- Testing
- LOU064
- Where
- 13 sites in Japan
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Myelodysplastic Syndromes, Leukemia Myeloid Acute
A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms
This is a post-authorization, retrospective multicentre observational nationwide study (PAS-OD). It will be conducted by reviewing medical records and database of patients who participated in the validation of the psychometric…
- Conditions
- Myelodysplastic Syndromes, Leukemia Myeloid Acute, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell
- Trial name
- NCT02842229
- Where
- 15 sites in Spain
- Volunteers
- 117 people
- Sponsor
- Celgene
Diabetic Foot Ulcer
Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot Ulcers
This study randomly assigns patients with diabetic foot ulcers to receive standard therapy (surgical debridement, saline-moistened gauze and offloading) alone or standard therapy plus Dermagraft(R).
- Trial name
- NCT01181453
- Testing
- Dermagraft, Comparator
- Where
- United States
- Volunteers
- 314 people
- Sponsor
- Organogenesis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.